Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Field Trials

26 Nov 2008 07:00

RNS Number : 9440I
Plant Health Care PLC
26 November 2008
 



26 November 2008

Plant Health Care plc ("Plant Health Care" or the "Company")

Results of the ASA Sponsored N-Hibit Seed Treatment Program

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries and  the American Soybean Association ("ASA") are pleased to announce that the "N-Hibit® Seed Treatment Satisfaction Guarantee" program during the 2008 growing season was an unqualified success.

The results of the N-Hibit Seed Treatment program over 17 replicated trial sites, ranging from Ohio to Nebraska, produced N-Hibit-treated yields averaging 62.0 bushels/acre compared to the untreated control average of 58.6 bushels/acre. This represents a yield increase of 3.4 bushels/acre or 5.8 per cent. As a consequence, less than 3 per cent. of the acreage treated with N-Hibit resulted in requests for refunds under the Seed Treatment Satisfaction Guarantee Program. The combined effect of nematode reduction and enhanced plant growth are the primary reasons for these excellent results.

ASA President John Hoffman, a soybean producer from Waterloo, Iowa, commented:

"ASA partnered with PHC on the project because part of ASA's mission is to help identify new ways for ASA members to maximize soybean yield and profitability. N-Hibit's ability to reduce SCN damage and boost overall plant health is consistent with that mission, so ASA worked with PHC to make our members aware of the Satisfaction Guarantee program."

Rick Rice, Plant Health Care Director, Sales & Marketing, USA Agricultural Division stated:

"We wanted growers to share our confidence, and the Satisfaction Guarantee program assured them of a full refund of the purchase price paid for N-Hibit if they weren't fully satisfied with its performance on treated acreage. With a better than 97 percent success rate and the relationships we have developed with all the farmers involved in the program, we couldn't be more pleased." 

The active ingredient in N-Hibit is harpin protein, which stimulates the same plant growth response that occurs when a plant experiences stress. The induced response results in a healthier plant and a reduction in the number of nematodes that host on the roots. Harpin proteins do not enter the plant. They bind with the plant's external harpin protein receptors, which are present on both seed and foliage. After the proteins initiate the plant's natural self defense and growth systems, they harmlessly disintegrate. For more information about PHC, please visit www.planthealthcare.com.

  For more information contact: 

John Hoffman, ASA President +001 (319) 233 9480

John Brady, Plant Health Care plc CEO +001 603 525 3702

Evolution Securities Limited +44 (0)20 7071 4300

Tim Worlledge / Tim Redfern

Tavistock Communications Limited +44 (0)20 7920 3150

Jeremy Carey / Matt Ridsdale

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAAFSAFXPFAE
Date   Source Headline
20th Apr 20227:00 amRNSHolding(s) in Company
19th Apr 20221:46 pmRNSNotice of results and investor presentation
11th Apr 202212:52 pmRNSHolding(s) in Company
1st Apr 20227:00 amRNSNew Distribution agreement with Ager Agro
14th Mar 202212:49 pmRNSHolding(s) in Company
11th Mar 202212:19 pmRNSHolding(s) in Company
3rd Feb 202212:56 pmRNSHolding(s) in Company
1st Feb 20221:16 pmEQSPlant Health Care, plc
1st Feb 20227:00 amRNS2021 Trading Statement
31st Jan 20227:00 amRNSPHC949 product registration submitted to the EPA
17th Jan 20227:00 amRNSInvestor Presentation
15th Dec 20217:00 amRNSWilbur Ellis and Plant Health Care discussion
13th Dec 20217:00 amRNSCommercial scale manufacturer for Saori
30th Nov 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20216:03 pmRNSExercise of Options
22nd Sep 20217:00 amRNSNew agreement with Nutrien for Saori launch
22nd Sep 20217:00 amRNSInterim Report 30 June 2021
21st Sep 20214:41 pmRNSSecond Price Monitoring Extn
21st Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.